Tarsus to Present at the Jefferies 2022 Healthcare Conference
May 27 2022 - 9:00AM
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to
focus on unmet needs and apply proven science and new technology to
revolutionize treatment for patients, starting with eye care, today
announced that Bobak Azamian, M.D., Ph.D., President and Chief
Executive Officer of Tarsus, will present a corporate update at the
Jefferies 2022 Healthcare Conference on Wednesday, June 8, 2022 at
8:30am PT / 11:30am ET.
A live webcast and additional information about the presentation
can be accessed on the events section of the Tarsus website at
www.tarsusrx.com. The replay will be available on the Tarsus
website within 48 hours and will be archived for a limited
time.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new
technology to revolutionize treatment for patients, starting with
eye care. Tarsus is advancing its pipeline to address several
diseases with high unmet need across a range of therapeutic
categories, including eye care, dermatology, and infectious disease
prevention. Tarsus is studying two investigational medicines in
clinical trials. Its lead product candidate, TP-03, is a novel
therapeutic which has demonstrated positive results in two pivotal
trials for the treatment of Demodex blepharitis. TP-03 is also
being developed for the treatment of Meibomian Gland Disease. In
addition, Tarsus is developing TP-05, an oral, non-vaccine
therapeutic for the prevention of Lyme disease, which is currently
being studied in a Phase 1b clinical trial.
Contacts: Media Contact:Adrienne KempSr.
Director, Corporate Communications(949)
922-0801AKemp@tarsusrx.com
Investor Contact:David NakasoneHead of Investor Relations(949)
620-3223DNakasone@tarsusrx.com
Tarsus Pharmaceuticals (NASDAQ:TARS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tarsus Pharmaceuticals (NASDAQ:TARS)
Historical Stock Chart
From Sep 2023 to Sep 2024